Lyra Therapeutics, Inc. (LYRA)
- Previous Close
5.23 - Open
5.25 - Bid 5.21 x 100
- Ask 5.25 x 100
- Day's Range
5.13 - 5.27 - 52 Week Range
2.26 - 6.79 - Volume
51,543 - Avg. Volume
345,850 - Market Cap (intraday)
312.456M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.26 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
lyratherapeutics.comRecent News: LYRA
Performance Overview: LYRA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYRA
Valuation Measures
Market Cap
312.46M
Enterprise Value
236.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
167.19
Price/Book (mrq)
3.49
Enterprise Value/Revenue
151.85
Enterprise Value/EBITDA
-3.63
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.43%
Return on Equity (ttm)
-73.67%
Revenue (ttm)
1.56M
Net Income Avi to Common (ttm)
-62.68M
Diluted EPS (ttm)
-1.26
Balance Sheet and Cash Flow
Total Cash (mrq)
102.75M
Total Debt/Equity (mrq)
30.06%
Levered Free Cash Flow (ttm)
-33.73M